HYFT MindWalk Holdings Corp. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1715925 · Reporting currency CAD · Fiscal year ends 04/30
Financial factors as of 2026-01-31 (2026Q3), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | 2026Q3*2026-01-31 | 2025Q2*2025-10-31 | 2025Q1*2025-07-31 | 2025Q4*2025-04-30 | 2025Q3*2025-01-31 | 2024Q2*2024-10-31 | 2024Q1*2024-07-31 | 2024Q4*2024-04-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 4.16M | 4.12M | 3.16M | 6.98M | 2.73M | 2.68M | 2.47M | 6.46M |
| Cost of revenue | 1.69M | 1.46M | 1.63M | 2.52M | 967,000 | 1.31M | 1.46M | 3.35M |
| Gross profit | 2.46M | 2.66M | 1.53M | 4.46M | 1.76M | 1.37M | 1.01M | 3.11M |
| R&D expense | 1.21M | 1.23M | 1.05M | 1.09M | 914,000 | 1.01M | 1.49M | 927,000 |
| SG&A expense | 3.12M | 3.07M | 3.29M | 3.71M | 2.86M | 2.85M | 3.35M | 4.12M |
| Pretax income | -3.95M | -3.19M | -4.18M | -1.90M | -24.96M | -4.28M | -4.88M | -18.82M |
| Income tax | -18,000 | 25,000 | -91,000 | 261,000 | -3.01M | -731,000 | -666,000 | -1.21M |
| Net income | -3.93M | -3.19M | -2.96M | -2.16M | -21.52M | -2.55M | -4.00M | -17.61M |
| EPS (basic) | — | — | — | — | -0.66 | -0.09 | -0.15 | — |
| EPS (diluted) | — | — | — | — | -0.66 | -0.09 | -0.15 | — |
| Balance sheet | ||||||||
| Cash & equivalents | 14.20M | 16.64M | 5.02M | 10.79M | 13.01M | 3.62M | 4.00M | 3.54M |
| Inventory | 490,000 | 531,000 | 524,000 | 2.10M | 1.92M | 2.01M | 1.87M | 2.14M |
| Current assets | 18.82M | 21.74M | 36.26M | 18.75M | 20.74M | 12.50M | 11.02M | 11.49M |
| PP&E, netmay include right-of-use assets (IFRS) | 4.02M | 4.21M | 4.34M | 15.76M | 15.22M | 15.96M | 16.44M | 16.70M |
| Goodwill | 0 | 0 | 0 | 8.23M | 7.87M | 7.92M | 7.85M | 7.69M |
| Intangibles | 0 | 0 | 0 | 1.07M | 1.12M | 23.01M | 23.42M | 23.56M |
| Total assets | 22.99M | 26.10M | 40.75M | 44.44M | 45.53M | 59.96M | 59.30M | 59.99M |
| Current liabilities | 5.03M | 5.19M | 16.69M | 9.01M | 8.93M | 12.41M | 11.17M | 8.12M |
| Total liabilities | 8.13M | 8.40M | 20.00M | 20.82M | 20.41M | 27.29M | 26.45M | 24.31M |
| Shareholders' equity | 14.86M | 17.71M | 20.74M | 23.63M | 24.95M | 31.89M | 32.84M | 35.68M |
| Shares outstanding | — | — | 46.15M | 46.15M | 45.77M | 30.29M | 27.30M | 26.94M |
| Cash flow statement | ||||||||
| Operating cash flow | -2.97M | -2.87M | -4.21M | -1.14M | -1.20M | -2.24M | -1.82M | -2.64M |
| Capital expenditure | 31,000 | 74,000 | 282,000 | 359,000 | 112,000 | 65,000 | 263,000 | 1.13M |
| Free cash flow | -3.00M | -2.94M | -4.50M | -1.50M | -1.31M | -2.31M | -2.09M | -3.77M |
| Investing cash flow | -12.89M | -74,000 | -594,000 | -359,000 | -112,000 | -65,000 | -263,000 | -1.11M |
| Financing cash flow | -13.31M | 14.08M | -371,000 | -418,000 | 10.55M | 2.07M | 2.70M | 1.12M |
| Depreciation & amortization | 217,000 | 207,000 | 942,000 | 913,000 | 1.40M | 1.42M | 1.40M | 1.58M |
| Stock-based compensation | 257,000 | 153,000 | 55,000 | 53,000 | 70,000 | 176,000 | 165,000 | 237,000 |
Free plan shows the latest 8 periods; Pro shows all 14 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.